Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecule against psoriasis

23.11.2006
A number of chronic diseases break out because the body attacks an imaginary enemy. A research group at the Norwegian University of Science and Technology (NTNU) has created a molecule that prevents our immune system from running wild.

When the body thinks it is under attack, it defends itself in the best way possible, for instance by starting a defence inflammation.

This reaction is highly appropriate if the enemy is an influenza virus or something else that actually needs to be fought. However, sometimes the body misinterprets the signals, and starts a defence inflammation against a non-existent enemy.

The result could be so-called autoimmune diseases: psoriasis, arthritis, Bechterew’s, asthma, allergies, ulcerative colitis, multiple sclerosis, Crohn’s disease – and numerous others.

... more about:
»Disease »Psoriasis

The list is longer than we care to imagine, and affects large parts of the population.

“Judas enzyme” sends the wrong message

Professor Berit Johansen at the Department of Biology at NTNU previously discovered which enzyme that misinterprets signals and reprograms cells to divide much faster than they should – thus provoking disease.

The enzyme is called phospholipase A2, less formally known as the “Judas enzyme”.

Now, Professor Johansen and her research group have created various stop molecules that prevent the “Judas enzyme” from sending the wrong messages to the cell nucleus. By doing so, the inflammatory reaction can be prevented.

One of these stop molecules was recently tested in mice infected with psoriasis. The results are more than promising: Every single mouse got better, in all respects.

In addition, it turned out that a high dosage yielded better effect than a low dosage.

Medical testing right around the corner

This discovery means that a substantial part of the road to a new type of medication is history. The next step is testing on humans.

Early next year, the substance will be available as a cream, ready to be applied on the first test persons. This testing will take place in France.

Professor Berit Johansen’s new firm, Avexxin, is also testing out two other molecules, one against rheumatoid arthritis, and one against nephritis.

By Hege Tunstad and Lisa Olstad/Gemini Research Journal

Nina Tveter | alfa
Further information:
http://www.ntnu.no/indexe.php

Further reports about: Disease Psoriasis

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>